Capstone Asset Management Co. Has $153,000 Stake in SciClone Pharmaceuticals Inc. (SCLN)
Capstone Asset Management Co. decreased its position in SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 0.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 14,960 shares of the specialty pharmaceutical company’s stock after selling 110 shares during the period. Capstone Asset Management Co.’s holdings in SciClone Pharmaceuticals were worth $153,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of SCLN. Acrospire Investment Management LLC acquired a new position in shares of SciClone Pharmaceuticals during the first quarter worth about $103,000. Mason Street Advisors LLC purchased a new position in shares of SciClone Pharmaceuticals during the second quarter worth $127,000. Rational Advisors LLC purchased a new position in shares of SciClone Pharmaceuticals during the second quarter worth $140,000. Profund Advisors LLC purchased a new position in shares of SciClone Pharmaceuticals during the second quarter worth $141,000. Finally, Algert Global LLC purchased a new position in shares of SciClone Pharmaceuticals during the third quarter worth $146,000. 79.60% of the stock is currently owned by institutional investors and hedge funds.
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) opened at 10.02 on Friday. The firm has a 50-day moving average price of $10.30 and a 200-day moving average price of $11.83. The stock has a market cap of $500.39 million, a price-to-earnings ratio of 13.52 and a beta of 1.47. SciClone Pharmaceuticals Inc. has a one year low of $7.13 and a one year high of $15.02.
SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share for the quarter. SciClone Pharmaceuticals had a return on equity of 24.43% and a net margin of 24.02%. The company earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. On average, equities analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current year.
In other news, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $10.62, for a total value of $82,857.24. Following the transaction, the chief financial officer now owns 25,000 shares of the company’s stock, valued at $265,500. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Nancy T. Chang sold 25,040 shares of the business’s stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $10.30, for a total value of $257,912.00. Following the completion of the transaction, the director now directly owns 29,019 shares in the company, valued at approximately $298,895.70. The disclosure for this sale can be found here. 7.63% of the stock is owned by company insiders.
About SciClone Pharmaceuticals
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals Inc. (NASDAQ:SCLN).
Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.